Interpace Diagnostics Group, Inc. (IDXG) is a publicly traded company in the Unknown sector. Across all available filings, 12 corporate insiders have executed 32 transactions totaling $354.3K, demonstrating a bullish sentiment with $354.3K in net insider flow. The most recent transaction on Jan 20, 2026 involved a transaction of 28,000 shares valued at $0.
No significant insider buying has been recorded for IDXG in the recent period.
No significant insider selling has been recorded for IDXG in the recent period.
Based on recent SEC filings, insider sentiment for IDXG is bullish with an Insider Alignment Score of 100/100 and a net flow of $354.3K. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Interpace Diagnostics Group, Inc. (IDXG) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 12 insiders are actively trading IDXG stock, having executed 32 transactions in the past 90 days. The most active insider is 2018 Limited Partnership Ampersand (Executive), who has made 2 transactions totaling $28.0M.
Get notified when executives and directors at IDXG file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 20, 2026 | Limited Partnership Ampersand 2018 | Executive | Conversion | 28,000 | $N/A | $0 | |
| Jan 20, 2026 | Limited Partnership Ampersand 2018 | Executive | Conversion | 13,861,386 | $2.02 | $28.0M | Large |
| Feb 1, 2024 | Mccarthy Christopher | Executive | Award | 10,000 | $N/A | $0 | |
| Jul 31, 2023 | Mccarthy Christopher | Executive | Award | 25,000 | $N/A | $0 | |
| May 21, 2021 | W. Burnell Thomas | Executive | Purchase | 10,855 | $8.68 | $94.2K | |
| Mar 1, 2021 | Kamin Peter | Executive | Purchase | 8,252 | $3.08 | $25.4K | |
| Mar 1, 2021 | Kamin Peter | Executive | Purchase | 2,862 | $3.08 | $8.8K | |
| Mar 1, 2021 | Kamin Peter | Executive | Purchase | 14,726 | $3.08 | $45.4K | |
| Mar 1, 2021 | Kamin Peter | Executive | Purchase | 16,360 | $3.08 | $50.4K | |
| Feb 26, 2021 | Kamin Peter | Executive | Purchase | 2,897 | $3.17 | $9.2K | |
| Feb 26, 2021 | Kamin Peter | Executive | Purchase | 8,333 | $3.17 | $26.4K | |
| Feb 26, 2021 | Kamin Peter | Executive | Purchase | 14,946 | $3.17 | $47.4K | |
| Feb 26, 2021 | Kamin Peter | Executive | Purchase | 14,874 | $3.17 | $47.2K | |
| Jan 29, 2021 | J. Gorman Robert | Executive | Award | 12,438 | $4.02 | $50.0K | |
| Dec 1, 2020 | W. Burnell Thomas | Executive | Award | 125,000 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Conversion(C) | 2 | $28.0M | 97.5% |
Purchase(P) | 9 | $354.3K | 1.2% |
Award(A) | 19 | $320.0K | 1.1% |
Payment(F) | 1 | $36.6K | 0.1% |
Exercise(M) | 1 | $0 | 0.0% |
Insiders at Interpace Diagnostics Group, Inc. are accumulating shares at an accelerated pace. With 12 insiders making 32 transactions totaling $354.3K in purchases versus $0 in sales, the net buying activity of $354.3K signals strong executive confidence. 2018 Limited Partnership Ampersand (Executive) leads the buying activity with $28.0M in transactions across all time.